^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IL1RAP overexpression

    i
    Other names: IL1RAP, Interleukin 1 Receptor Accessory Protein, IL-1RAcP, C3orf13, IL1R3, Interleukin-1 Receptor Accessory Protein, IL-1 Receptor Accessory Protein, Interleukin-1 Receptor 3, Interleukin-1 Receptor Accessory Protein Beta, IL-1R-3, IL-1R3
    Entrez ID:
    3556
    1year
    Tumor IL1RAP levels and reduction in serum biomarkers correlate with response in PDAC patients treated with nadunolimab, an anti-IL1RAP monoclonal antibody, in combination with gemcitabine and nab-paclitaxel (AACR 2023)
    Nadunolimab combined with GN shows promising iPFS and OS in 73 PDAC patients. In these patients, high tumor cell expression of IL1RAP, the molecular target for nadunolimab, correlated with response. Reduction of the downstream biomarkers IL-6 and IL-8, as well as CRP, were most pronounced in responding patients and correlated with efficacy.
    Clinical • Combination therapy
    |
    IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • IL1B (Interleukin 1, beta) • IL1RAP (Interleukin 1 Receptor Accessory Protein) • CRP (C-reactive protein)
    |
    IL1RAP overexpression
    |
    gemcitabine • albumin-bound paclitaxel • nadunolimab (CAN04)